[PDF] Top 20 Desenvolvimento motor da criança em idade pré-escolar : estudo exploratório com crianças de 4 e 5 anos

... for neovascular AMD found an improvement in mean visual acuity from 20/184 to 20/109 at 3 months (Spaide et al ...central macular thickness decreased from 340 µ m to 247 µ m over the same ... See full document

... intravitreal ranibizumab injection for treating patients with neovascular age-related macular degeneration (AMD) from 2007 to ...with neovascular AMD (mean age of ... See full document

... to neovascular age-related macular degeneration who were treated within a nine- month time frame and completed the six-month follow- up were included in the ...of ranibizumab ... See full document

... treating neovascular age-related macular degeneration ...from ranibizumab to aflibercept led to an improvement in eyes with recalcitrant ...with neovascular AMD were ... See full document

... Materials and methods: We searched PubMed, Wed of Science, Cochrane Library, EMBASE, Google Scholar, Medline, China National Knowledge Infrastructure, and WANFANG DATA databases, up to June 20, 2018. We also searched ... See full document

... of ranibizumab for neovascular age-related macular degeneration, which included an independent economic evaluation ...a ranibizumab injection, which, when converted to US ... See full document

... to ranibizumab and were switched to aflibercept (AF group), 8 patients who received ranibizumab and photody- namic therapy (PDT group), and 13 patients who responded to ranibizumab (control ...for ... See full document

... lesions and 45 eyes with minimally classic lesions or occult no classic lesions. Twenty-eight eyes (56%) had received previous treatment for nAMD (12 eyes [24%] had received bevacizumab intravitreal injection and 16 eyes ... See full document

... Neovascular AMD was diagnosed in patients who were older than 50 and showed exudative changes from chor- oidal neovascularization (CNV) on fluorescein angiography (FA) and SD-OCT. This study excluded cases of ... See full document

... monthly ranibizumab therapy for 3 months followed by 4–6 weekly review and pro-re-nata ...a macular scan using optical coherence tomography, slit-lamp biomicroscopy, and were then injected with ... See full document

... Sixty consecutive participants were enrolled from September 2016 to March 2017 at the Spedali Civili Ophthalmic Center (Spedali Civili di Brescia) in Brescia, Italy. Patients were randomized (online statistical computing ... See full document

... three ranibizumab injections and underwent scans using the fast RNFL thickness protocol (Stratus optical coherence tomography) before starting the first injection and 1 month after the third ...choroidal ... See full document

... [10–13] Ranibizumab [10, 11, 13–22] and Aflibercept [10, ...involving ranibizumab, some studies have reported improvement in VA [14, 15] whereas others have reported variable visual results with no ... See full document

... acuity gradually decreased during long-term follow-up with retreatment using a pro re nata regimen when patients exited from the MARINA or ANCHOR trial. These findings indi- cated that anti-VEGF therapy is a long and ... See full document

... of Ranibizumab in Subjects with Subfoveal Choroidal Neovasularization with or without Classic CNV Secondary to Age-Related Macular Degeneration; PIER) patients received injections of ... See full document

... Associations between changes in BCVA or CFT mea- sured by OCT and type of treatment (Ranibizumab or Aflibercept) after completing the 3 month loading phase, were assessed with two multivariate mixed linear models. ... See full document

... Certain biological principles suggest that radiation may be an effective treatment modality for wet AMD. This is based on the concept that the development of neovascular AMD is similar to a proliferative wound ... See full document

... We included 291 eyes of 291 patients. The mean age was 75 years (ranging from 35–95 years), with 64.3% of the patients being women. One hundred seventy-one eyes were phakic, 114 were pseudophakic, and 6 were ... See full document

... to ranibizumab or bevacizumab is harder to explain but may be due to the different molecular structure of the ...to ranibizumab, or vice versa ...in macular fluid in 81 % of patients with choroidal ... See full document

... The World Health Assembly in May 2013 adopted a new global programme document entitled “Universal Eye Health: a global action plan 2014-2019” [1]. It states the major priorities for the global prevention of blindness ... See full document